Health Care [ 2/12 ] | Biotechnology [ 3/73 ]
NASDAQ | Common Stock
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma.
The company is headquartered in Frederick, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 25 | -0.77 Decreased by -220.69% | -0.82 Increased by +5.80% |
| May 8, 25 | -0.65 Increased by +18.75% | -0.71 Increased by +8.45% |
| Mar 5, 25 | -0.59 Decreased by -747.86% | -0.83 Increased by +28.12% |
| Nov 7, 24 | -0.42 Decreased by -600.00% | -0.55 Increased by +23.64% |
| Aug 8, 24 | 0.64 Increased by +1.01 K% | -0.09 Increased by +811.11% |
| May 8, 24 | -0.80 Decreased by -471.43% | -1.42 Increased by +43.66% |
| Mar 7, 24 | -0.07 Decreased by -275.00% | -0.04 Decreased by -75.00% |
| Nov 13, 23 | -0.06 Decreased by -20.00% | -0.06 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 298.00 K Decreased by -99.11% | 15.89 M Increased by +14.82% | Increased by +5.33 K% Increased by +12.79 K% |
| Mar 31, 25 | 1.10 M Decreased by -81.16% | -17.71 M Increased by +68.83% | Decreased by -1.61 K% Decreased by -65.47% |
| Dec 31, 24 | -759.00 K Decreased by -109.18% | -10.25 M Increased by +94.23% | Increased by +1.35 K% Increased by +162.85% |
| Sep 30, 24 | 387.00 K Decreased by -94.09% | -24.18 M Decreased by -168.64% | Decreased by -6.25 K% Decreased by -4.45 K% |
| Jun 30, 24 | 33.45 M Increased by +537.17% | 13.84 M Increased by +221.51% | Increased by +41.37% Increased by +119.07% |
| Mar 31, 24 | 5.84 M Decreased by -1.65% | -56.82 M Decreased by -162.31% | Decreased by -973.01% Decreased by -166.71% |
| Dec 31, 23 | 8.27 M Decreased by -50.78% | -177.66 M Decreased by -3.11 K% | Decreased by -2.15 K% Decreased by -6.23 K% |
| Sep 30, 23 | 6.55 M Decreased by -68.37% | -9.00 M Decreased by -14.05% | Decreased by -137.41% Decreased by -260.55% |